BiocurePharm Corporation announced a non-brokered private placement of 12,500 shares at issue price of CAD 4.328 per share for gross proceeds of CAD 54,100 on January 16, 2023. The transaction included participation from returning investor Biocure Technology Inc. and it holds a 93.42-per-cent interest in the company.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.01 CAD | 0.00% |
|
-33.33% | -33.33% |
Jun. 30 | Atriva Therapeutics GmbH cancelled the acquisition of Biocure Technology Inc. | CI |
May. 21 | Biocure Technology Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
1st Jan change | Capi. | |
---|---|---|
-33.33% | 689K | |
+16.37% | 21.21B | |
-6.72% | 2.44B | |
+40.70% | 2.4B | |
-7.44% | 1.6B | |
-6.20% | 1.05B | |
-27.92% | 627M | |
-13.76% | 272M |
- Stock Market
- Equities
- CURE.X Stock
- News Biocure Technology Inc.
- BiocurePharm Corporation announced that it has received CAD 0.0541 million in funding from Biocure Technology Inc.